0000000000349963

AUTHOR

Hélène Poquet

showing 4 related works from this author

3q27.3 microdeletional syndrome: a recognisable clinical entity associating dysmorphic features, marfanoid habitus, intellectual disability and psych…

2013

Abstract: Background Since the advent of array-CGH, numerous new microdeletional syndromes have been delineated while others remain to be described. Although 3q29 subtelomeric deletion is a well-described syndrome, there is no report on 3q interstitial deletions. Methods We report for the first time seven patients with interstitial deletions at the 3q27.3q28 locus gathered through the Decipher database, and suggest this locus as a new microdeletional syndrome. Results The patients shared a recognisable facial dysmorphism and marfanoid habitus, associated with psychosis and mild to severe intellectual disability (ID). Most of the patients had no delay in gross psychomotor acquisition, but ha…

AdultMalePsychosisCandidate genePediatricsmedicine.medical_specialtyAdolescentLocus (genetics)ArachnodactylyYoung AdultIntellectual DisabilityIntellectual disabilityGeneticsMedicineHumansAbnormalities MultipleGenetics (clinical)GeneticsComparative Genomic Hybridizationbusiness.industryMood DisordersMarfanoidChromosome MappingFaciesInfantSyndromemedicine.diseasePhenotypeMood disordersChild PreschoolBone maturationFemaleHuman medicineChromosomes Human Pair 3Chromosome DeletionbusinessJournal of medical genetics
researchProduct

Transcranial Magnetic Stimulation Combined With Nicotine Replacement Therapy for Smoking Cessation: A Randomized Controlled Trial.

2015

Abstract Background Further evidence suggests that repetitive Transcranial Magnetic Stimulation (rTMS) is an effective method to reduce tobacco craving among smokers. Hypothesis As relapse is common within a few days after smoking cessation, we hypothesized that combining the anti-craving effects of rTMS with Nicotine replacement therapy (NRT) to attenuate withdrawal symptoms could increase abstinence rates in smokers with severe nicotine dependence who quit smoking. Methods Thirty-seven smokers who failed to quit with the usual treatments were randomly assigned to two treatment groups to receive either active ( n  = 18) or sham ( n  = 19) 1-Hz rTMS of the right dorsolateral prefrontal cort…

CessationAdultMaleNicotinemedicine.medical_specialtymedicine.medical_treatmentmedia_common.quotation_subjectBiophysicsPrefrontal CortexCravingbehavioral disciplines and activitieslcsh:RC321-571law.inventionNicotineYoung AdultRandomized controlled triallawTobaccomental disordersmedicineHumansSingle-Blind MethodPsychiatrylcsh:Neurosciences. Biological psychiatry. Neuropsychiatrymedia_commonCravingGeneral NeuroscienceTobacco Use DisorderAbstinenceMiddle AgedNicotine replacement therapyCombined Modality TherapyTranscranial Magnetic StimulationTobacco Use Cessation DevicesTranscranial magnetic stimulationTreatment Outcomenervous systemAnesthesiaCombinationbehavior and behavior mechanismsSmoking cessationFemaleSmoking CessationNeurology (clinical)medicine.symptomTobacco Use Cessation ProductsPsychologypsychological phenomena and processesmedicine.drugBrain stimulation
researchProduct

20 ans après: a second mutation in MAOA identified by targeted high-throughput sequencing in a family with altered behavior and cognition

2013

Intellectual disability (ID) is characterized by an extraordinary genetic heterogeneity, with >250 genes that have been implicated in monogenic forms of ID. Because this complexity precluded systematic testing for mutations and because clinical features are often non-specific, for some of these genes only few cases or families have been unambiguously documented. It is the case of the X-linked gene encoding monoamine oxidase A (MAOA), for which only one nonsense mutation has been identified in Brunner syndrome, characterized in a single family by mild non-dysmorphic ID and impulsive, violent and aggressive behaviors. We have performed targeted high-throughput sequencing of 220 genes, includi…

MaleModels MolecularBrunner syndromeNonsense mutationMutation MissenseArticleIntellectual DisabilityGeneticsmedicineMissense mutationHumansGenetic Predisposition to DiseaseAmino Acid SequenceMonoamine OxidaseGenetics (clinical)GeneticsFamily HealthbiologyBase SequenceGenetic heterogeneityPoint mutationHigh-Throughput Nucleotide Sequencingmedicine.diseasePedigreeProtein Structure TertiaryAutism spectrum disorderAttention Deficit and Disruptive Behavior DisordersChild Development Disorders Pervasivebiology.proteinAutismFemaleMonoamine oxidase A
researchProduct

Intragenic FMR1 disease-causing variants: a significant mutational mechanism leading to Fragile-X syndrome

2017

International audience; Fragile-X syndrome (FXS) is a frequent genetic form of intellectual disability (ID). The main recurrent mutagenic mechanism causing FXS is the expansion of a CGG repeat sequence in the 5'-UTR of the FMR1 gene, therefore, routinely tested in ID patients. We report here three FMR1 intragenic pathogenic variants not affecting this sequence, identified using high-throughput sequencing (HTS): a previously reported hemizygous deletion encompassing the last exon of FMR1, too small to be detected by array-CGH and inducing decreased expression of a truncated form of FMRP protein, in three brothers with ID (family 1) and two splice variants in boys with sporadic ID: a de novo …

Male0301 basic medicinemedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesdiagnosisRNA SplicingBiologymedicine.disease_causePolymorphism Single NucleotideArticleFragile X Mental Retardation Protein03 medical and health sciencesExonGenetic linkageplacebo-controlled trial[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMolecular geneticsGeneticsmedicineHumansgeneGenetics (clinical)GeneticsMutationintron 10SiblingsMiddle Agedmedicine.diseaseFMR1Human genetics3. Good healthFragile X syndromedevelopmental delayof-the-literature030104 developmental biologyintellectual disabilityFragile X SyndromeMutationmental-retardationMedical geneticsFemalepoint mutationdouble-blind[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct